Individuals with growth hormone receptor deficiency may also possess a surprising advantage when it comes to cardiovascular health. A recent study suggests that individuals with growth hormone receptor deficiency (GHRD), a rare genetic mutation also known as Laron syndrome, may have a lower risk of cardiovascular disease (CVD). GHRD is characterized by an impaired ability by the body to use its own growth hormone; this leads to stunted growth, but it has been associated with an incredible 40% lifespan extension in mice, as well as reduced risk for age-related disease risks in mice [1]. However ..read more

Longevity Week is set to take place in the German capital for the first time in a move that will grow Berlin’s event landscape. Berlin is set to play host to Longevity Week for the first time. Kicking off with an opening event on 6th May at the Langenbeck-Virchow-Haus in Berlin Mitte near the Charité hospital, the week will see a total of 15 events happening in the city, throughout Longevity Week, which runs from the 6th to the 12th May 2024. Speakers include, among others, Professor Eric Verdin, CEO of renowned Buck Institute, Michael Greve from Kizoo Technology Capital and Dr Ina Czyborram ..read more

New research looks at the impact of calorie restriction on telomere length, shedding light on the complex relationship between diet and aging. The role played by diet – when, how and what we eat – has been of keen interest for geroscience researchers. Calorie restriction, in particular, has come under the spotlight due to its potential to seemingly slow down the aging process and extend lifespan. Now, a new study from Penn State University has explored into the intricate mechanisms behind calorie restriction, focusing on its effect on telomeres — the protective caps at the ends of chromosomes ..read more

Company also advances precision therapeutics for neurodegenerative diseases including Alzheimer’s, ALS and frontotemporal dementia. Precision therapeutics company Cerevance has announced a $47 million Series B-1 extension funding round to advance its programs in central nervous system disorders. The financing is intended to support the company into a Phase 3 clinical trial for the company’s investigational non-dopamine therapy (CVN424) for Parkinson’s disease, as well as advancing its therapeutic pipeline in Alzheimer’s, ALS and frontotemporal dementia. Currently undergoing Phase 2 evaluation ..read more

High-throughput in vivo screening platform can test hundreds of gene therapies simultaneously in animals closely mirroring human biology. Gordian Biotechnology launched today, with $60 million in venture capital and a groundbreaking platform aimed at revolutionizing the discovery of gene therapies for age-related diseases. The San Francisco-based company specializes in in vivo drug discovery and development and claims its approach to screening potential treatments provides unprecedented accuracy and efficiency. Central to Gordian’s platform is its use of “patient avatars,” animal models that c ..read more

Mitrix Bio CEO on how targeting increased longevity for astronauts could also pay dividends for those back on Planet Earth. Mitrix Bio recently announced the creation of a new subsidiary, Biotech Explorers, that is aiming to achieve a 130 year lifespan in humans. Initially focused on astronauts, and bringing benefits for those suffering from early-aging diseases, the trials will transplant bioreactor-grown mitochondria into volunteers to increase the number of functional mitochondria. Longevity.Technology: In addition to extended lifespan, Biotech Explorers also hopes to demonstrate rapid woun ..read more

Following compelling preclinical results, Repair Bio’s cholesterol-degrading platform is gearing up for clinical trials in atherosclerosis. Following the recent revelation that its cholesterol-degrading technology rapidly reverses the progression of atherosclerosis in multiple preclinical models, gene therapy company Repair Biotechnologies is now moving forward with plans to move into human trials. Having received favorable initial feedback, the New York-based biotech is raising funding as it prepares for further discussions with the US FDA as it aims to advance its therapies into clinical tri ..read more

Senescence-targeting biotech links up with beauty company behind multiple skin care brands, including NIVEA. Hot on the heels of its recent funding news, Rubedo Life Sciences has announced a strategic partnership with German beauty giant Beiersdorf AG. The partnership aims to pioneer innovative skin care products addressing the effects of cellular aging, exploring novel compounds sourced from Rubedo’s programs targeting cellular senescence. Senescent cells, which accumulate with age, are believed to contribute to age-related skin changes and pathologies. Rubedo has advanced programs in this ar ..read more

Xandro is on a mission to make science-based wellness nutrition accessible for everyone. For some longevity supplement companies, their job is done when you buy their product; not Xandro, which takes a wraparound approach, sharing research on its ingredients for informed decision-making beforehand, and hosting a community that enables individuals from all walks of life that share a common passion for health and wellness. Longevity.Technology: Singapore-based Xandro wants to catalyze positive change in the longevity supplements industry with a brand that emphasizes accessibility, quality and co ..read more

Company aims to leverage AI to ‘connect the world of biological targets and engineered molecules to the human experience of disease.’ AI drug discovery company Xaira Therapeutics has launched with more than $1 billion in funding as it seeks to reshape the landscape of medicine. The San Francisco-based company is built on three core pillars: leveraging machine learning to better understand biology, generating the data needed to create new models of disease, and ultimately developing “robust therapeutic products” for the treatment of a wide range of diseases. The company was incubated by ARCH Ve ..read more